Vera Therapeutics (VERA) | Financial Analysis & Statements
Vera Therapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-94.2M
Net Income
-91.1M
Balance Sheet Metrics
Total Assets
734.7M
Total Liabilities
130.2M
Shareholders Equity
604.5M
Debt to Equity
0.22
Cash Flow Metrics
Operating Cash Flow
-75.7M
Free Cash Flow
-70.1M
Revenue & Profitability Trend
Vera Therapeutics Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 215.3M | 126.2M | 78.2M | 69.0M | 22.5M |
| Selling, General & Administrative | 100.2M | 41.0M | 23.8M | 21.9M | 11.9M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 315.5M | 167.2M | 102.0M | 90.9M | 34.4M |
| Operating Income | -315.5M | -167.2M | -102.0M | -90.9M | -34.4M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 24.5M | 20.7M | 8.0M | 1.8M | 15.0K |
| Interest Expense | 7.5M | 7.6M | 3.8M | 992.0K | 20.0K |
| Other Non-Operating Income | -1.1M | 1.9M | 1.8M | 1.1M | 1.8M |
| Pre-tax Income | -299.6M | -152.1M | -96.0M | -89.1M | -32.6M |
| Income Tax | 1.0K | 1.0K | 1.0K | 1.0K | 1.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -299.6M | -152.1M | -96.0M | -89.1M | -32.6M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -291.6M | -144.4M | -92.2M | -87.3M | -34.2M |
| EPS (Basic) | - | $-2.75 | $-2.25 | $-3.35 | $-2.43 |
| EPS (Diluted) | - | $-2.75 | $-2.25 | $-3.35 | $-2.43 |
| Basic Shares Outstanding | - | 55326680 | 42707072 | 26570676 | 13435706 |
| Diluted Shares Outstanding | - | 55326680 | 42707072 | 26570676 | 13435706 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Vera Therapeutics Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 354.7M | 92.6M | 45.7M | 43.5M | 79.7M |
| Short-term Investments | 359.9M | 548.2M | 115.0M | 71.2M | 0 |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 2.5M | 913.0K | 3.2M | 719.0K | 480.0K |
| Total Current Assets | 728.9M | 651.2M | 172.0M | 125.7M | 82.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.4M | 960.0K | 92.0K | 51.0K | 0 |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.6M | 131.0K | 482.0K | 513.0K | 344.0K |
| Total Non-Current Assets | 5.8M | 4.5M | 3.5M | 5.7M | 1.2M |
| Total Assets | 734.7M | 655.7M | 175.5M | 131.4M | 83.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 21.9M | 7.7M | 11.1M | 12.0M | 1.4M |
| Short-term Debt | 549.0K | 1.5M | 2.4M | 2.6M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.4M | - | - | - | 377.0K |
| Total Current Liabilities | 53.5M | 25.4M | 22.3M | 25.6M | 7.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 76.8M | 53.2M | 51.3M | 28.6M | 4.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | 1.3M |
| Total Non-Current Liabilities | 76.8M | 53.2M | 51.6M | 28.9M | 6.5M |
| Total Liabilities | 130.2M | 78.5M | 73.9M | 54.5M | 14.2M |
| Equity | |||||
| Common Stock | 71.0K | 64.0K | 44.0K | 28.0K | 21.0K |
| Retained Earnings | -760.9M | -461.2M | -309.1M | -213.1M | -124.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 604.5M | 577.2M | 101.7M | 76.9M | 69.6M |
| Key Metrics | |||||
| Total Debt | 77.3M | 54.6M | 53.7M | 31.3M | 4.9M |
| Working Capital | 675.4M | 625.8M | 149.7M | 100.1M | 74.8M |
Balance Sheet Composition
Vera Therapeutics Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -299.6M | -152.1M | -96.0M | -89.1M | -32.6M |
| Depreciation & Amortization | 468.0K | 105.0K | -4.1M | -846.0K | 176.0K |
| Stock-Based Compensation | 37.9M | 20.8M | 11.5M | 8.9M | 3.0M |
| Working Capital Changes | 12.5M | -5.5M | -3.8M | 7.9M | 424.0K |
| Operating Cash Flow | -244.6M | -133.9M | -90.2M | -67.3M | -25.0M |
| Investing Activities | |||||
| Capital Expenditures | -630.0K | -972.0K | -63.0K | -62.0K | 0 |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -310.4M | -703.0M | -224.9M | -148.5M | 0 |
| Investment Sales | 506.2M | 279.0M | 185.6M | 78.0M | 0 |
| Investing Cash Flow | 194.3M | -425.0M | -39.4M | -70.6M | -5.0M |
| Financing Activities | |||||
| Share Repurchases | 0 | -13.0K | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 23.3M | 0 | 24.7M | 19.8M | 4.9M |
| Debt Repayment | - | - | - | - | 0 |
| Financing Cash Flow | 301.9M | 593.3M | 132.5M | 99.8M | 53.3M |
| Free Cash Flow | -241.7M | -135.7M | -92.2M | -67.7M | -23.7M |
| Net Change in Cash | 251.6M | 34.4M | 2.9M | -38.0M | 23.3M |
Cash Flow Trend
Vera Therapeutics Key Financial Ratios
Valuation Ratios
Forward P/E
-13.23
Price to Book
4.75
PEG Ratio
-13.23
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-50.71%
Return on Assets
-28.36%
Financial Health
Current Ratio
13.64
Debt to Equity
12.79
Beta
1.17
Per Share Data
EPS (TTM)
$-4.66
Book Value per Share
$8.48
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VERA | 2.8B | - | 4.75 | -50.71% | 0.00% | 12.79 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






